Pitch Perfect

Johnston, Josephine
January 2012
Scientist;Jan2012, Vol. 26 Issue 1, p24
The article focuses on the issue of academic detailing related to the pharmaceutical industry in the U.S. It highlights the American Recovery and Reinvestment Act, which directed funds amounting 150 billion dollars to health care. It states that comparative effectiveness research is different from the clinical trials that drug and device companies conduct to obtain U.S. Food and Drug Administration (FDA) approval. It adds that academic detailing was developed by Jerry Avorn and colleagues.


Related Articles

  • Adeona receives additional funding for multiple sclerosis trial.  // PharmaWatch: CNS;Feb2010, Vol. 9 Issue 2, p4 

    The article reports that the clinical trial for Adeona Pharmaceuticals Inc.'s multiple sclerosis (MS) drug, Trimesta, received 860,440 dollars in grant funding from the American Recovery and Reinvestment Act in the U.S. It notes that the clinical trial had received five million dollars grant...

  • Comparative Effectiveness Regulations and Pharmaceutical Innovation. Vernon, John A.; Golec, Joseph H.; Stevens, J. Stedman // PharmacoEconomics;2010, Vol. 28 Issue 10, p877 

    As healthcare reform evolves and takes shape, comparative effectiveness research (CER) appears to be one of the central topics on the national healthcare agenda. Over the past couple of years, comparative effectiveness has been explicitly incorporated in more than ten bills. For example, the...

  • Forum.  // Pharmaceutical Medicine - New Zealand;2009, Vol. 23 Issue 2, p107 

    The article covers issues related to the pharmaceutical sector as of April 2009. Margaret Chan, World Health Organization (WHO) director-general, has noted in a statement that the global economic crisis is affecting world health. U.S. National Institute of Health (NIH) Raynard Kington has...

  • FDA snubbed in stimulus. von Eschenbach, Andrew C.; Oliver, Wayne W. // Hill;10/8/2009, Vol. 16 Issue 115, p28 

    The author presents his views on on the omission of the U.S. Food and Drug Administration (FDA) from the 2009 economic stimulus package.

  • INDEPENDENT CLINICAL TRIALS TO TEST DRUGS: THE NEGLECTED REFORM. RODWIN, MARC A. // Journal of Health Law & Policy;2012, Vol. 6 Issue 1, p113 

    The article focuses on the reform proposals precluding the bias in the clinical trials used in drug testing in the U.S. It mentions that the federal government has pursued alternative strategies to counter bias when the reform proposal was neglected for over half a century due to the opposition...

  • COBRA assistance may be extended. Geisel, Jerry // Business Insurance;10/12/2009, Vol. 43 Issue 36, p01 

    This article reports on the intention of the administration of U.S. President Barack Obama to extend the COBRA health care premium subsidy in 2009. The subsidy is embedded in the American Recovery and Reinvestment Act of 2009. The program aims to help unemployed people and their families. Some...

  • what is the Recovery Act's dedicated Medicaid funding ultimately stimulating? Brooke, Kari // hfm (Healthcare Financial Management);Aug2009, Vol. 63 Issue 8, p32 

    The article discusses the issues concerning the funds provided by the American Recovery and Reinvestment Act (ARRA) of 2009 to the health care sector in the U.S. It promises clear benefits for the sector, despite widespread disagreement about its effectiveness for the nation's economic recovery....

  • Health Care, Research Benefit from Funds. Lusis, Ingrida; Moss, Sharon // ASHA Leader;5/5/2009, Vol. 14 Issue 6, p1 

    The article reports that more than $87 billion in funds from the U.S. American Recovery and Reinvestment Act (ARRA) is for health care provisions, including to the National Institutes of Health for research, Medicaid, hospitals, community health centers, and health information technology....

  • A Look Behind the Numbers. Belyeu, Kathy // WindLetter;May2010, Vol. 29 Issue 5, p1 

    The article reports on the condition of the wind industry in the U.S. for 2009 and 2010. It states that the wind industry had installed 10,000 megawatts in 2009 boosted by the American Recovery and Reinvestment Act and 539 megawatts were commissioned in the first quarter of 2010 which is lower...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics